Pulmonary mucormycosis in the aftermath of critical COVID-19 in an immunocompromised patient: Mind the diagnostic gap

Crone, C; Helweg‐Larsen, Jannik; Steensen, Morten; Arendrup, Maiken Cavling; Helleberg, Marie

doi:10.1016/j.mycmed.2021.101228

Cited by 10 publications

(13 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, in a patient with uncontrolled diabetes whose CT thorax shows RHS, the evaluation for mucormycosis should continue despite microbiological and serological evidence of aspergillosis. 85 …”

Section: Resultsmentioning

confidence: 99%

Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India

Muthu

Agarwal

Patel

et al. 2022

The Lancet Infectious Diseases

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India

Muthu

Agarwal

Patel

et al. 2022

The Lancet Infectious Diseases

View full text Add to dashboard Cite

“…Clinical features in patient with mucormycosis depends on the site of infection. For example, rhinocerebral infections present with headache, facial pain, check swelling and eye swelling [ 11 ]. pulmonary mucormycosis presents with nonspecific symptoms.…”

Section: Discussionmentioning

confidence: 99%

“…There is no serological test available to confirm the diagnosis [ 13 , 16 ]. However Molecular techniques such as polymerase chain reaction (PCR) may allow early and definitive diagnosis in a short period of time, which may improve the outcome [ 3 , 8 ].…”

Section: Discussionmentioning

confidence: 99%

“…Despite the risk of renal toxicity, high-dose liposomal Amphotericin B (5–10 mg/kg/day) [ 16 ] is the medication of choice for treating Mucorales spp. Furthermore, all currently available Azole antifungal agents have less effect against mucormycosis; however, itraconazole, isavuconazole and oral posaconazole are used against mucormycosis as alternative in patients with preexisting renal compromise [ 16 ] (the incidence of renal injury is significantly lower with isavuconazonium) [ 4 ].Voriconazole is not indicated due to the poor susceptibility of Mucorales to this drug [ 16 ]. Although some studies have found that combining two antifungals reduces mortality when compared to monotherapy, however these medications are frequently of limited role without surgical intervention (Arana et al, 2021).…”

Section: Discussionmentioning

confidence: 99%

“…In patients with pulmonary mucormycosis, surgical treatment with radical removal of infarcted tissue is the key to improve the results [ 16 ] which ought to be done as soon as possible in order to prevent the dissemination [ 13 ].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Pulmonary mucormycosis after renal transplantation: A case report and a literature review

asabeh

Zeer

Dukmak

et al. 2022

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Comparative risk assessment of COVID‐19 associated mucormycosis and aspergillosis: A systematic review

Baral

Aziz

Islam

2022

Health Science Reports

View full text Add to dashboard Cite

COVID‐19 is not only limited to a defined array but also has expanded with several secondary infections. Two uncommon opportunistic fungal infections, COVID‐19 associated mucormycosis (CAM) and aspergillosis (CAA), have recently been highly acquainted by many worldwide cases. Two immune response deteriorating factors are considered to be responsible for immunosuppression: comorbidities and medication. Due to unlike infection sites and patterns, CAM and CAA‐associated factors deflect a few degrees of proximity, and the present study is for its assessment. The study evaluated 351 CAM cases and 191 CAA cases retrieved from 65 and 53 articles based on inclusion criteria, respectively. Most of the CAM reported from India and CAA were from four South‐European and West‐European neighbor countries. The mean ages of CAM and CAA were 52.72 ± 13.74 and 64.81 ± 11.14, correspondingly. Mortality of CAA (56.28%) was two times greater than CAM (26.02%). Nevertheless, the count of diabetes cases was very high in CAM compared to CAA. The main comorbidities of CAM were diabetes (nearly 80%) and hypertension (more than 38%). All noticeable complications were higher in CAA except diabetes, and these were diabetes (34.55%), hypertension (45.03%), and obesity (18.32%). Moreover, pre‐existing respiratory complications like asthma and chronic obstructive pulmonary disease are visible in CAA. The uses of steroids in CAM and CAA were nearly 70% and 66%, respectively. Almost one‐fourth of CAA cases were reported using immunosuppressant monoclonal antibodies, whereas only 7.69% were for CAM. The overall finding highlights diabetes, hypertension, and steroids as the risk factors for CAM, whereas obesity, chronic pulmonary disease, and immunosuppressants for CAA.

show abstract

Pulmonary mucormycosis in the aftermath of critical COVID-19 in an immunocompromised patient: Mind the diagnostic gap

Cited by 10 publications

References 19 publications

Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India

Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India

Pulmonary mucormycosis after renal transplantation: A case report and a literature review

Comparative risk assessment of COVID‐19 associated mucormycosis and aspergillosis: A systematic review

Contact Info

Product

Resources

About